GVK Biosciences (GVK BIO), one of Asia's leading drug discovery research and development CRO has entered into a collaboration agreement with U.S. based Endo Pharmaceuticals focused on discovering novel small molecules targeting an exciting protein.
Under this agreement GVK BIO will use its discovery expertise to deliver a clinical candidate and Endo will develop and commercialize the product arising out of this collaboration. This collaboration arose out of a newly launched concept at GVK BIO named Early Discovery Assets (EDA).
GVK Biosciences, through its internal expertise in computational chemistry, discovery biology and medicinal chemistry, is building a portfolio of discovery project assets for potential early stage partnering. This early stage asset portfolio is focused around pain and inflammation. GVK Biosciences develops these assets to a stage of demonstrated value and then looks to partner and co-develop them with life science companies.
Mr Manni Kantipudi, CEO of GVK BIO commented, "We are delighted to partner with Endo as it continues to build its discovery pipeline through external collaborations. This collaboration also confirms the value of our differentiated EDATM concept, conceived to collaborate with pharmaceutical partners on discovery projects, from target to clinical candidates."
Dr. Sandeep Gupta, Endo's Senior Vice President of Drug Discovery and Early Development stated, "We are pleased to initiate this discovery collaboration with GVK BIO. With their world class infrastructure and an experienced scientific team, I have no doubt that they will execute on the program goals and add to our portfolio of development candidates that provide novel treatment options for the patients".